Contact Info:
- Email: clinicaltrials@cabalettabio.com
- Phone: +1 (267) 759-3100
A phase 1/ 2 clinical trial, investigating a treatment that uses your own T cells to treat myositis
Who Can Participate:
- Children ages 6+ and adults with active myositis (JDM, JPM, or adult forms)
- Must have active disease
- Learn more here
A study physician will determine final eligibility.
How It Works:
- T cells are extracted from the patient, reengineered into CAR T cells, and returned to the patient to target harmful immune cells that may be causing disease
- All participants in the RESET-Myositis Trial will receive CAR-T cell therapy— there is no placebo group in this study
- Learn more about the CAR-T process and how it works here
The trial is enrolling at multiple locations across the U.S., including:
Sites enrolling pediatric patients age 6-26*
- Chicago, IL (Comer Children’s, University of Chicago)
- Chicago, IL (Lurie Children’s Hospital)
- San Francisco, CA (UCSF)
- Philadelphia, PA (CHOP)
- Ann Arbor, MI (University of Michigan)
- New York, NY (Hospital for Special Surgery)
- New York, NY (Memorial Sloan Kettering Cancer Center)
- The Bronx, New York (Children’s Hospital at Montefiore)
- Seattle, WA (Seattle Children’s)
- Not yet recruiting: Aurora, Colorado (Children’s Hospital Colorado)
- Not yet recruiting: Bethesda, Maryland (NIH)
- More locations listed here
Sites enrolling age 18+
- Orange County, CA (UC Irvine)
- Jacksonville, FL (Mayo Clinic)
- Nashville, TN (Vanderbilt)
- Houston, TX (Houston Methodist & MD Anderson)
- Kansas City, MO (UMKC)
- Rochester, MN (Mayo Clinic)
- Portland, OR (OHSU)
- Atlanta, GA (Emory)
- United Kingdom: London, Manchester, Salford
- More locations listed here
*Each institution may have slightly different maximum age guidelines, please contact clinicaltrials@cabalettabio.com to learn more
Travel:
- Travel to one of the sites may be covered, please contact to learn more
Want to learn more?
Talk to your doctor or email the study team at clinicaltrials@cabalettabio.com
Read more about this trial on clinicaltrials.gov
New Publication in Nature Biotechnology
A recent publication reviews the clinical progress of cellular immunotherapies for autoimmune diseases, including data from the RESET program evaluating rese-cel.
The full publication can be found here.
